Endometrial cancer (WP4155)

Homo sapiens

Open in new tab Open in NDEx Open in Newt (SBGN)
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads
Endometrial cancer (EC) is the most common gynecological malignancy and the fourth most common malignancy in women in the developed world after breast, colorectal and lung cancer. Two types of endometrial carcinoma are distinguished with respect to biology and clinical course. Type-I carcinoma is related to hyperestrogenism by association with endometrial hyperplasia, frequent expression of estrogen and progesterone receptors and younger age, whereas type-II carcinoma is unrelated to estrogen, associated with atrophic endometrium, frequent lack of estrogen and progesterone receptors and older age. The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy, p53 mutations, and her2/neu amplification. Phosphorylation sites were added based on information from PhosphoSitePlus (R), www.phosphosite.org. Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP4155 CPTAC Assay Portal]

Authors

Kristina Hanspers , Alex Pico , Friederike Ehrhart , Egon Willighagen , and Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

CPTAC Diseases

Annotations

Pathway Ontology

endometrial cancer pathway disease pathway cancer pathway

Cell Type Ontology

epithelial cell of uterus

Disease Ontology

endometrial cancer

Participants
Query Drugst.One

Label Type Compact URI Comment
Trastuzumab Metabolite wikidata:Q412616
Lenvatinib Metabolite chebi:85994
Ponatinib Metabolite chebi:78543
Cenersen sodium Metabolite wikidata:Q27275465
PIP3 Metabolite hmdb:HMDB0004249
Brivanib Metabolite wikidata:Q27075503
Nintedanib Metabolite chebi:85164
Dovitinib Metabolite wikidata:Q27077102
EGF GeneProduct ensembl:ENSG00000138798
FOS GeneProduct ensembl:ENSG00000170345
EGFR GeneProduct ensembl:ENSG00000146648
GRB2 GeneProduct ensembl:ENSG00000177885
SOS1 GeneProduct ensembl:ENSG00000115904
SOS2 GeneProduct ensembl:ENSG00000100485
HRAS GeneProduct ensembl:ENSG00000174775
KRAS GeneProduct ensembl:ENSG00000133703
NRAS GeneProduct ensembl:ENSG00000213281
ARAF GeneProduct ensembl:ENSG00000078061
BRAF GeneProduct ensembl:ENSG00000157764
RAF1 GeneProduct ensembl:ENSG00000132155
MAP2K1 GeneProduct ensembl:ENSG00000169032
MAP2K2 GeneProduct ensembl:ENSG00000126934
MAPK1 GeneProduct ensembl:ENSG00000100030
MAPK3 GeneProduct ensembl:ENSG00000102882
ELK1 GeneProduct ensembl:ENSG00000126767
PTEN GeneProduct ensembl:ENSG00000171862
PIK3CA GeneProduct ensembl:ENSG00000121879
PIK3CB GeneProduct ensembl:ENSG00000051382
PIK3CD GeneProduct ensembl:ENSG00000171608
PIK3R1 GeneProduct ensembl:ENSG00000145675
PIK3R2 GeneProduct ensembl:ENSG00000105647
PIK3R3 GeneProduct ensembl:ENSG00000117461
PDPK1 GeneProduct ensembl:ENSG00000140992
ILK GeneProduct ensembl:ENSG00000166333
AKT1 GeneProduct ensembl:ENSG00000142208
AKT2 GeneProduct ensembl:ENSG00000105221
AKT3 GeneProduct ensembl:ENSG00000117020
FOXO3 GeneProduct ensembl:ENSG00000118689
BAD GeneProduct ensembl:ENSG00000002330
CASP9 GeneProduct ensembl:ENSG00000132906
CDH1 GeneProduct ensembl:ENSG00000039068
CTNNB1 GeneProduct ensembl:ENSG00000168036
CTNNA1 GeneProduct ensembl:ENSG00000044115
CTNNA2 GeneProduct ensembl:ENSG00000066032
CTNNA3 GeneProduct ensembl:ENSG00000183230
AXIN1 GeneProduct ensembl:ENSG00000103126
AXIN2 GeneProduct ensembl:ENSG00000168646
APC GeneProduct ensembl:ENSG00000134982
APC2 GeneProduct ensembl:ENSG00000115266
GSK3B GeneProduct ensembl:ENSG00000082701
TCF7 GeneProduct ensembl:ENSG00000081059
LEF1 GeneProduct ensembl:ENSG00000138795
TCF7L1 GeneProduct ensembl:ENSG00000152284
TCF7L2 GeneProduct ensembl:ENSG00000148737
CCND1 GeneProduct ensembl:ENSG00000110092
MYC GeneProduct ensembl:ENSG00000136997
ERBB2 GeneProduct ensembl:ENSG00000141736
BAX GeneProduct ensembl:ENSG00000087088
CDKN1A GeneProduct ensembl:ENSG00000124762
DDB2 GeneProduct ensembl:ENSG00000134574
GADD45A GeneProduct ensembl:ENSG00000116717
GADD45B GeneProduct ensembl:ENSG00000099860
GADD45G GeneProduct ensembl:ENSG00000130222
BAK1 GeneProduct ensembl:ENSG00000030110
POLK GeneProduct ensembl:ENSG00000122008
TP53 GeneProduct ensembl:ENSG00000141510
FGFR2 GeneProduct ensembl:ENSG00000066468
FGF1 GeneProduct ensembl:ENSG00000113578
FGF2 GeneProduct ensembl:ENSG00000138685
FGFR1 GeneProduct ensembl:ENSG00000077782
FGFR3 GeneProduct ensembl:ENSG00000068078

References

  1. Ets-related protein Elk-1 is homologous to the c-fos regulatory factor p62TCF. Hipskind RA, Rao VN, Mueller CG, Reddy ES, Nordheim A. Nature. 1991 Dec 19;354(6354):531–4. PubMed Europe PMC Scholia
  2. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Buza N, Roque DM, Santin AD. Arch Pathol Lab Med. 2014 Mar;138(3):343–50. PubMed Europe PMC Scholia
  3. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. Nucleic Acids Res. 2015 Jan;43(Database issue):D512-20. PubMed Europe PMC Scholia
  4. Targeting fibroblast growth factor pathways in endometrial cancer. Winterhoff B, Konecny GE. Curr Probl Cancer. 2017;41(1):37–47. PubMed Europe PMC Scholia